This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Looks like ruthenium might take much longer than expected. 90p placing don't look good at all.

Any one heard the latest rumour..

Go on Mitzy, what is the latest?.....

LOL

there isnt one..!

And I hoped there was a rumour of a 10 a share bid coming !!! Ah well, back to work !!

guess we will have to wait a while longer neil.

Yes indeed Mitzy but this ones always been one for the patient.

Nice to hear from you again.

And you gf all quiet on the eastern front.

At last could we be hearing some good news soon re a tie up ..I will believe it when I see it.
I remember when they were 6p and trebled in a week those were the days.

Mitzy, I certainly do hope there is some sort of positive news, whether it is re a tie up, or perhaps some test results that exceed expectations etc. Either way, I firmly believe in the long term future of this share, even though it also a very frustrating experience being a shareholder !

What a terrible performance the last week back to 100p level and some investors giving up hope and I dont blame them.I hope we have onfo on the influenza vaccine invivro tests a possible big winner .
I remain confident we will hear from DB by end of the year.

Yes Mitzy, a dreadful week..... It is difficult to maintain confidence in the face of a falling shareprice, but I'm sticking with this one for now, there will hopefully be some sort of good news soon re the ongoing trials.

One of the main things to remember is that if any of the trials had shown up bad results, they would have to announce this to the market innediately, and there have been no such announcements. In fact, all announcements have been very positive.

One day this will be a share worth many times the current value - I just hope I'm still around to see it !!!

thanks neil its a difficult one to call right now.

My problem is that whatever happens it will be a long-time. ( Phase trials - commercialisation could be 10-years I fear). That give competitors plenty of time to find a universal cure, thereby making this technique no more than a curiosity. Chemotherepy is an unpleasant treatment and I'm not convinced that a slightly better product is really what is needed.
The cash position is OK, I understand; however, it won't be too long before they are back and I suspect this will have to be below the 90p a few months ago.

Their silencing route is a further drain on resources (which I was unaware of until now) - however good it might be - - - what it does is speed up the Cash-Call and this is the reason the sp is slipping . . . since I suspect that during 2008 you'll be able to buy these under 1. Even a 20p-fall would have a considerable effect on investment profitability - this was 1.60 only recently, yet 80p would buy you twice as many ( or reduce the wad, we PI's need punt.) and that's when I'll invest if all other considerations are right.
I hold a few, to keep tabs on developments.

You are right, hangon. MMG was into Ruthenium compounds a couple of years ago and not much has been heard of recently. Now they are into gene-silencing which Silence (SLN) is also in it. R&D spending is decreasing whilst administration and directors payments are increasing. I think MMG has lost its aim.
It is a SELL...

Medical Marketing International H1 loss climbs on administrative expenses UPDATE - AFX


(Adds CEO, CFO comment)

LONDON (Thomson Financial) - Medical Marketing International PLC's first half pretax losses rose to 1.97 mln stg, compared with 1.74 mln a year ago, as a result of increased administrative costs related to remuneration and other expenses.

The company's research and development spending was around 900,000 stg during the period, down from 1.05 mln this time last year.

Administrative costs, including director and staff remuneration, were 1.27 mln stg, up from 1.02 mln. Cash at the period end was 3.9 mln, compared with 7.4 mln last year. It said that it has enough cash for at least another year.

Medical Marketing's most recent fund raising round was a 10 mln stg placing in 2005.

The company has a pipeline of cancer vaccines and chemotherapy medicines, all in early stage development.

Medical Marketing CEO David Best said: 'The focus of the whole business is now on achieving these commercialisation trigger-points so that latent value can be turned into real value.'

The company's gene silencing technology is an area of great interest for big pharma companies. 'They seem to be in a land grab on this,' Best told Thomson Financial News.

CFO Rob Sprawson said that R&D spending is dependent on scheduling and is determined after each set of results.

The company does not expect the 'spending mix' to change going into next year, Sprawson said.

julian.hofmann@thomson.com

The question is are they worth buying now at 80p or bit longer to buy 70p ish.

we need a deal and soon.

70p could still be too expensive for MMG with no products in market for many years now. All in research and no outcome yet.

65p now.